The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Interim safety and efficacy results from a phase 1 study of NT219 in adults with advanced solid tumors.
 
Alberto Bessudo
No Relationships to Disclose
 
Ezra E.W. Cohen
Stock and Other Ownership Interests - Kinnate Biopharma
Consulting or Advisory Role - Bayer; BioNTech; Debiopharm Group; Eisai; Gilead Sciences; Merck; MSD; Regeneron
 
Rodolfo Gutierrez
Research Funding - Immunocore (Inst); Immunocore (Inst)
 
Daniel H. Johnson
Leadership - BrightPath Biotheraputics
Honoraria - BrightPath Biotheraputics
Speakers' Bureau - Bristol-Myers Squibb/Pfizer
 
Ari Rosenberg
Stock and Other Ownership Interests - Galectin Therapeutics
Consulting or Advisory Role - EMD Serono; Nanobiotix
Research Funding - Sysmex
 
Benjamin Adam Weinberg
Employment - Apple (I)
Stock and Other Ownership Interests - Apple (I)
Honoraria - Rafael Pharmaceuticals
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Bayer; HalioDx
Speakers' Bureau - AstraZeneca; Bayer; Diiachi Sankyo; HalioDx; Lilly; Sirtex Medical; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Ipsen (Inst); Isofol Medical (Inst); Novartis (Inst)
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - Boehringer Ingelheim; Caris Life Sciences
 
Susanna Varkey Ulahannan
Consulting or Advisory Role - Array BioPharma; Bayer; Eisai; Incyte; Syros Pharmaceuticals
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); ArQule (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); atreca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CicloMed (Inst); Erasca, Inc (Inst); evelo biosciences (Inst); Exelixis (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); IgM Biosciences (Inst); Incyte (Inst); Klus Pharma (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Synermore biologics (Inst); Takeda (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); Tesaro (Inst); Vigeo Therapeutics (Inst)
 
Hadas Reuveni
Employment - Purple Biotech; TyrNovo
Leadership - Purple Biotech; TyrNovo
Stock and Other Ownership Interests - Purple Biotech; TyrNovo
Patents, Royalties, Other Intellectual Property - co-inventor on TyrNovo's patents
 
Michael Schickler
Employment - Purple Biotech
Leadership - Purple Biotech
Stock and Other Ownership Interests - Purple Biotech
Consulting or Advisory Role - Accellta; Immunorizon
Travel, Accommodations, Expenses - Purple Biotech
 
Bertrand C. Liang
Employment - Purple Biotech
Leadership - Purple Biotech
Stock and Other Ownership Interests - Kitov Pharmaceuticals
Consulting or Advisory Role - Kitov Pharmaceuticals
Research Funding - Purple Biotech
Travel, Accommodations, Expenses - Kitov Pharmaceuticals